<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-95099</identifier>
<setSpec>1696-7240</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Overview of adjuvant treatment in early breast cancer</dc:title>
<dc:description xml:lang="en">The benefits of adjuvant systemic therapy in reducing risk of distant relapse form breast cancer have been recognized for several decades. The intent of adjuvant therapy is to eliminate the occult micrometastatic breast cancer burden before it progresses into clinically apparent disease. Decisions regarding adjuvant therapy are increasingly complex with the advent of new therapeutic strategies, a growing body of literature on the molecular biology and natural history of breast cancer, and advances in therapeutic techniques and early detection. Systemic chemotherapy is an integral component of the adjuvant treatment strategy for women who have early-stage breast cancer and accounts for significant improvements in breast cancer-specific mortality. Endocrine therapy plays a pivotal role in the early treatment of estrogen receptor (ER)=- positive breast cancer. Successful delivery of effective adjuvant systemic therapy as a complement to surgical management of breast cancer has contributed to the steady declines in breast cancer mortality observed internationally over the past 2 decades. Four large randomized trials to assess efficacy and toxicity of trastuzumab in adjuvant systemic therapy of breast cancer have been initiated. Results clearly demonstrate, that adjuvant treatment of trastuzumab significantly improves outcomes for women with HER2 positive breast cancer (AU)</dc:description>
<dc:creator>Puente, Javier</dc:creator>
<dc:creator>Martín, Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El beneficio del tratamiento adyuvante del cáncer de mama ha sido bien establecido en las últimas décadas, logrando reducir el riesgo de recidiva sistémica. La finalidad de dicha terapia consiste en eliminar la enfermedad micrometastásica. Sin embargo, las opciones terapéuticas en este contexto se han incrementado con un mejor conocimiento de la historia natural del cáncer de mama y sus mecanismos moleculares involucrados, complicando así el árbol de decisión terapéutico. La quimioterapia ha constituido el armamentario fundamental del tratamiento complementario del cáncer de mama, consiguiéndose avances notables en el pronóstico de estas pacientes. Del mismo modo, el tratamiento hormonal juega un papel esencial en el tratamiento adyuvante del cáncer de mama con receptores hormonales positivos. Cuatro grandes ensayos randomizdos llevados a cabo con trastuzumab, ha permitido mejorar la supervivencia en pacientes con tumores HER2 positivos (AU)</dc:description>
<dc:source>Psicooncología (Pozuelo de Alarcón);4(2/3): 311-329, dic. 2007.</dc:source>
<dc:identifier>ibc-95099</dc:identifier>
<dc:title xml:lang="es">Actualización del tratamiento adyuvante en cáncer de mama</dc:title>
<dc:subject>^d32226</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1968^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d974^s22073</dc:subject>
<dc:subject>^d30193^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>200712</dc:date>
</metadata>
</record>
</ibecs-document>
